♥

Sun Pharmaceutical Industries Limited

ISIN : INE044A01036
NSE : SUNPHARMA
BSE : 524715
Face Value : 1
Industry : Pharmaceuticals & Drugs

EPS : 39.90
EPS (TTM) : 46.10
Price to Earning (P/E) : 43.48
Book Value : 265.36
Price to Bookvalue (P/B) : 6.54
Dividend Yield : 1 %
Return on Equity (ROE) : 16.13 %
Return on Capital Employed (ROCE) : 17.60 %

Sun Pharmaceutical share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	1665 - 1694.65 1.8 %
Low / High	1635.05 - 1700 4 %
Trade Volume	1.27 Lk
52 Week Low / High	1547.25 - 1850.95 19.6 %

YOU MAY ALSO LIKE

High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	107618	109523	112410	109307	119408	121924	123807	119829	126528	132914
Total Income	109096	110375	114148	113040	121473	124860	127555	125888	131853	137735
Total Expenditure	80230.4	79957.3	82372.5	81285.4	86111.1	90130.3	90284.3	89477.5	90451.3	94805.2
Other Income	1478.1	852.2	1738.8	3732.8	2064.8	2936.1	3747.6	6059.4	5325.5	4820.9
Operating Profit	28865.3	30417.7	31776	31754.1	35362.1	34729.9	37270.3	36410.9	41401.7	42929.6
Interest	136.9	193.9	461.8	927.4	808.8	492.9	347.3	735.7	615.4	691.7
Exceptional Items				-1714.5	-3228.7		-698.1	-1016.4
PBDT	28728.4	30223.8	31314.2	29112.2	31324.6	34237	36224.9	34658.8	40786.3	42237.9
Depreciation	5880	6099.5	6599.5	6715.3	6513.2	6328.2	6221.4	6503.6	6551.3	6259.1
Profit Before Tax	22848.4	24124.3	24714.7	22396.9	24811.4	27908.8	30003.5	28155.2	34235	35978.8
Tax	1889.9	1522.6	2834.3	2229.1	4681	3901	4323.2	1489.3	5522.5	5672.1
Profit After Tax	20958.5	22601.7	21880.4	20167.8	20130.4	24007.8	25680.3	26665.9	28712.5	30306.7
Net Profit	20958.5	22601.7	21880.4	20167.8	20130.4	24007.8	25680.3	26665.9	28712.5	30306.7
Equity Capital	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	8.59	9.43	9.03	8.27	8.43	9.9	10.52	11.06	11.82	12.67
Diluted Eps After Extraordinary Items	8.6	9.4	9	8.3	8.4	9.9	10.5	11.1	11.8	12.7
Diluted Eps Before Extraordinary Items	8.6	9.4	9	8.3	8.4	9.9	10.5	11.1	11.8	12.7

STANDALONE QUARTERLY RESULT FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	49328.8	52852.9	46457.5	59482.2	44660.7	50962.1	50737.5	56391.4	44980.7	51277.1
Total Income	51090.9	53270	47203.8	60685.2	46296.1	52121.4	53022.3	57580.2	45808.1	53423.4
Total Expenditure	36104.4	36221.2	36529.7	35875.7	35173.1	37192.8	38664.3	37456.1	37370	39174.2
Other Income	1762.1	417.1	746.3	1203	1635.4	1159.3	2284.8	1188.8	827.4	2146.3
Operating Profit	14986.5	17048.8	10674.1	24809.5	11123	14928.6	14358	20124.1	8438.1	14249.2
Interest	870.7	927.7	1308.9	1614.5	1579.4	1936.3	2149.2	2175.9	2160.8	2437.5
Exceptional Items				-29377.9	-1492.1		-698.1
PBDT	14115.8	16121.1	9365.2	-6182.9	8051.5	12992.3	11510.7	17948.2	6277.3	11811.7
Depreciation	3745	3839.5	4304.4	4119.8	4152.7	3927.1	3996	3930.4	3698.1	2855.3
Profit Before Tax	10370.8	12281.6	5060.8	-10302.7	3898.8	9065.2	7514.7	14017.8	2579.2	8956.4
Tax	252.8	151.5	193.5	-94.5	92.4	178.9	301.6	5341.8	201	323.5
Profit After Tax	10118	12130.1	4867.3	-10208.2	3806.4	8886.3	7213.1	8676	2378.2	8632.9
Net Profit	10118	12130.1	4867.3	-10208.2	3806.4	8886.3	7213.1	8676	2378.2	8632.9
Equity Capital	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	4.22	5.06	2.03	-4.25	1.59	3.7	3.01	3.62	0.99	3.6
Diluted Eps After Extraordinary Items	4.2	5.1	2	-4.3	1.6	3.7	3	3.6	1	3.6
Diluted Eps Before Extraordinary Items	4.2	5.1	2	-4.3	1.6	3.7	3	3.6	1	3.6

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	386545	438857	484968
Total Income	397300	445202	498872
Total Expenditure	284107	322389	355098
Other Income	10754.7	6345.2	13903.2
Operating Profit	113192	122813	143773
Interest	1273.5	1720	2384.7
Exceptional Items	-45668.2	-1714.5	-4943.2
PBDT	66250.6	119379	136445
Depreciation	21437.4	25294.3	25566.4
Profit Before Tax	44813.2	94084.3	110879
Tax	10755	8475.9	14394.5
Profit After Tax	34058.2	85608.4	96484.4
Net Profit	34058.2	85608.4	96484.4
Equity Capital	2399.3	2399.3	2399.3
Face Value (IN RS)	1	1	1
Reserves	477713	557554	634268
Calculated EPS	13.64	35.32	39.91
Diluted Eps After Extraordinary Items	13.6	35.3	39.9
Diluted Eps Before Extraordinary Items	13.6	35.3	39.9

STANDALONE ANNUAL RESULT FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	155860	208121	202752
Total Income	167829	211414	208286
Total Expenditure	129174	143895	147753
Other Income	11968.8	3292.9	5534.8
Operating Profit	38654.4	67518.9	60533.7
Interest	3881	4721.8	7840.8
Exceptional Items	-18205.3	-29377.9	-2190.2
PBDT	16568.1	33419.2	50502.7
Depreciation	13499.5	16008.7	16006.2
Profit Before Tax	3068.6	17410.5	34496.5
Tax	4068.5	503.3	5914.7
Profit After Tax	-999.9	16907.2	28581.8
Net Profit	-999.9	16907.2	28581.8
Equity Capital	2399.3	2399.3	2399.3
Face Value (IN RS)	1	1	1
Reserves	243480	235084	234545
Calculated EPS	-0.42	7.05	11.91
Diluted Eps After Extraordinary Items	-0.4	7	11.9
Diluted Eps Before Extraordinary Items	-0.4	7	11.9

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	61462.1 Cr	67191.4 Cr	74247.8 Cr	48496.8 Cr
Sales	61103.1 Cr	66963.3 Cr	73641 Cr	47130.4 Cr
Processing Charges / Service Income	0	0	0	628 Cr
Net Sales	33498.1 Cr	38654.5 Cr	43885.7 Cr	48496.8 Cr
Increase/Decrease in Stock	-638.22 Cr	-107.61 Cr	-686.91 Cr	292.13 Cr
Raw Material Consumed	9328.3 Cr	10459.2 Cr	11349.1 Cr	10370.5 Cr
Opening Raw Materials	2893.6 Cr	3344.17 Cr	2913.54 Cr	3478.45 Cr
Purchases Raw Materials	6603.7 Cr	6618.49 Cr	8342.48 Cr	6555.44 Cr
Closing Raw Materials	3344.17 Cr	2913.54 Cr	3478.45 Cr	3129.56 Cr
Other Direct Purchases / Brought in cost	3175.17 Cr	3410.03 Cr	3571.5 Cr	3466.15 Cr
Power & Fuel Cost	627.09 Cr	702.78 Cr	830.05 Cr	760.78 Cr
Electricity & Power	627.09 Cr	702.78 Cr	830.05 Cr	760.78 Cr
Employee Cost	6862.23 Cr	7300.83 Cr	8296.03 Cr	9429.06 Cr
Salaries, Wages & Bonus	6053.01 Cr	6444.47 Cr	7340.21 Cr	8331.01 Cr
Contributions to EPF & Pension Funds	431.29 Cr	469.09 Cr	514.12 Cr	529.4 Cr
Workmen and Staff Welfare Expenses	329.93 Cr	335.76 Cr	378.31 Cr	496.82 Cr
Other Manufacturing Expenses	1723.78 Cr	1880.71 Cr	1936.77 Cr	2186.62 Cr
Processing Charges	541.61 Cr	557.81 Cr	561.32 Cr	630.26 Cr
Repairs and Maintenance	528.44 Cr	524.6 Cr	656.51 Cr	779.57 Cr
General and Administration Expenses	3179.45 Cr	3270.55 Cr	4256.12 Cr	5252.93 Cr
Rent , Rates & Taxes	500.74 Cr	649.38 Cr	729.1 Cr	826.93 Cr
Insurance	236.02 Cr	261.7 Cr	299.49 Cr	304.35 Cr
Printing and stationery	53.26 Cr	60.61 Cr	66.57 Cr	170.58 Cr
Professional and legal fees	2023.54 Cr	1803.13 Cr	2312.3 Cr	2953.16 Cr
Traveling and conveyance	240.19 Cr	373.73 Cr	641.99 Cr	818.28 Cr
Selling and Distribution Expenses	3103.96 Cr	4075.02 Cr	5226.24 Cr	5780.26 Cr
Sales Commissions & Incentives	203.3 Cr	195.44 Cr	206.84 Cr	223.49 Cr
Freight and Forwarding	622.37 Cr	793.29 Cr	934.06 Cr	812.47 Cr
Miscellaneous Expenses	843.83 Cr	1191.25 Cr	1216.85 Cr	1675.51 Cr
Provision for doubtful debts	4.31 Cr	17.57 Cr	42.62 Cr	90.59 Cr
Loss on disposal of fixed assets(net)	2.24 Cr	13.81 Cr	3.65 Cr	30.77 Cr
Loss on foreign exchange fluctuations	0	0	126.1 Cr	0
Loss on sale of non-trade current investments	0	361.95 Cr	0	0
Total Expenditure	25030.4 Cr	28772.7 Cr	32424.2 Cr	35747.8 Cr
Other Income	859.17 Cr	1437.42 Cr	819.85 Cr	1628.24 Cr
Interest Received	211.13 Cr	553.37 Cr	384.54 Cr	1022.91 Cr
Dividend Received	256.04 Cr	215.33 Cr	146.45 Cr	103.3 Cr
Profit on sale of Fixed Assets	16.12 Cr	48.56 Cr	11.19 Cr	20.8 Cr
Provision Written Back	12.28 Cr	5.98 Cr	15.07 Cr	29.21 Cr
Foreign Exchange Gains	23.65 Cr	153.96 Cr	0	36.13 Cr
Operating Profit	9326.89 Cr	11319.2 Cr	12281.3 Cr	14377.3 Cr
Interest	141.43 Cr	127.35 Cr	172 Cr	238.47 Cr
PBDT	9185.46 Cr	11191.9 Cr	12109.3 Cr	14138.8 Cr
Depreciation	2079.95 Cr	2143.74 Cr	2529.43 Cr	2556.64 Cr
Profit Before Taxation & Exceptional Items	7105.51 Cr	9048.14 Cr	9579.88 Cr	11582.2 Cr
Exceptional Income / Expenses	-4306.14 Cr	-4566.82 Cr	-171.45 Cr	-494.32 Cr
Profit Before Tax	2799.37 Cr	4481.32 Cr	9408.43 Cr	11087.9 Cr
Provision for Tax	514.69 Cr	1075.5 Cr	847.59 Cr	1439.45 Cr
Current Income Tax	957.3 Cr	354.39 Cr	1869.22 Cr	1989.3 Cr
Deferred Tax	-442.61 Cr	721.11 Cr	-1021.63 Cr	-549.85 Cr
Profit After Tax	2284.68 Cr	3405.82 Cr	8560.84 Cr	9648.44 Cr
Minority Interest	631.47 Cr	-116.55 Cr	-39.36 Cr	-33.65 Cr
Share of Associate	-12.33 Cr	-16.54 Cr	-47.9 Cr	-38.41 Cr
Consolidated Net Profit	2903.82 Cr	3272.73 Cr	8473.58 Cr	9576.38 Cr
Profit Balance B/F	35320 Cr	36598.1 Cr	37645.6 Cr	43610.2 Cr
Appropriations	38223.9 Cr	39870.8 Cr	46119.2 Cr	53186.6 Cr
Other Appropriation	306.65 Cr	546.12 Cr	709.5 Cr	1093.65 Cr
Equity Dividend %	750	1000	1150	1350
Earnings Per Share	12.1	13.64	35.32	39.91
Adjusted EPS	12.1	13.64	35.32	39.91

STANDALONE PROFIT / LOSS FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	14469.6 Cr	15714.8 Cr	21772.1 Cr	20275.2 Cr
Sales	14237.3 Cr	15647.3 Cr	21354.6 Cr	19177.6 Cr
Processing Charges / Service Income	0	0	0	665.98 Cr
Net Sales	12803.2 Cr	15586 Cr	20812.1 Cr	20275.2 Cr
Increase/Decrease in Stock	-214.84 Cr	-183.18 Cr	-237.93 Cr	180.32 Cr
Raw Material Consumed	5008.74 Cr	5833.57 Cr	6292.09 Cr	5423.79 Cr
Opening Raw Materials	1153.23 Cr	1621.37 Cr	1413.87 Cr	1751.3 Cr
Purchases Raw Materials	4116.02 Cr	4377.47 Cr	5503.06 Cr	4047.2 Cr
Closing Raw Materials	1460.14 Cr	1413.87 Cr	1751.3 Cr	1369.12 Cr
Other Direct Purchases / Brought in cost	1199.63 Cr	1248.6 Cr	1126.46 Cr	994.41 Cr
Power & Fuel Cost	384.13 Cr	422.33 Cr	495.21 Cr	450.42 Cr
Electricity & Power	384.13 Cr	422.33 Cr	495.21 Cr	450.42 Cr
Employee Cost	1798.45 Cr	2000.78 Cr	2156.95 Cr	2373.95 Cr
Salaries, Wages & Bonus	1651.16 Cr	1826.57 Cr	1980.13 Cr	2170.33 Cr
Contributions to EPF & Pension Funds	81.49 Cr	88.33 Cr	96.1 Cr	107.65 Cr
Workmen and Staff Welfare Expenses	34.18 Cr	52.03 Cr	39.48 Cr	49.23 Cr
Other Manufacturing Expenses	840.09 Cr	1064.32 Cr	1037.32 Cr	1195.3 Cr
Processing Charges	203.83 Cr	275.23 Cr	313.75 Cr	344.45 Cr
Repairs and Maintenance	239.62 Cr	245.94 Cr	301.56 Cr	371.61 Cr
General and Administration Expenses	975.4 Cr	1447.23 Cr	1827.71 Cr	2187.01 Cr
Rent , Rates & Taxes	165.94 Cr	235.14 Cr	240.33 Cr	330.37 Cr
Insurance	73.98 Cr	80.23 Cr	87.58 Cr	85.2 Cr
Printing and stationery	20.44 Cr	19.4 Cr	20.8 Cr	65.28 Cr
Professional and legal fees	608.99 Cr	978.74 Cr	1241.5 Cr	1412.63 Cr
Traveling and conveyance	75.72 Cr	103.27 Cr	199.42 Cr	251.91 Cr
Selling and Distribution Expenses	796.69 Cr	2055.4 Cr	2498.71 Cr	2567.85 Cr
Sales Commissions & Incentives	46.6 Cr	23.25 Cr	25.95 Cr	23.73 Cr
Freight and Forwarding	292.92 Cr	314.25 Cr	378.84 Cr	275.98 Cr
Miscellaneous Expenses	289.88 Cr	276.97 Cr	319.48 Cr	396.64 Cr
Provision for doubtful debts	4.32 Cr	26.32 Cr	24.25 Cr	11.95 Cr
Loss on disposal of fixed assets(net)	9.97 Cr	0	0	14.6 Cr
Loss on foreign exchange fluctuations	14.88 Cr	0	0	0
Loss on sale of non-trade current investments	97 Lk	0	88 Lk	0
Total Expenditure	9878.54 Cr	12917.4 Cr	14389.5 Cr	14775.3 Cr
Other Income	161.55 Cr	1196.88 Cr	329.29 Cr	553.48 Cr
Interest Received	59.23 Cr	439.02 Cr	220.2 Cr	396.43 Cr
Dividend Received	38.34 Cr	13.54 Cr	0	0
Profit on sale of Fixed Assets	10.36 Cr	37.45 Cr	4.27 Cr	13 Lk
Profits on sale of Investments	0	207.57 Cr	0	0
Provision Written Back	7.56 Cr	4.88 Cr	12.85 Cr	21.56 Cr
Foreign Exchange Gains	0	238.96 Cr	50.26 Cr	87.72 Cr
Operating Profit	3086.22 Cr	3865.44 Cr	6751.89 Cr	6053.37 Cr
Interest	256.98 Cr	388.1 Cr	472.18 Cr	784.08 Cr
PBDT	2829.24 Cr	3477.34 Cr	6279.71 Cr	5269.29 Cr
Depreciation	586.81 Cr	1349.95 Cr	1600.87 Cr	1600.62 Cr
Profit Before Taxation & Exceptional Items	2242.43 Cr	2127.39 Cr	4678.84 Cr	3668.67 Cr
Exceptional Income / Expenses	-89.56 Cr	-1820.53 Cr	-2937.79 Cr	-219.02 Cr
Profit Before Tax	2152.87 Cr	306.86 Cr	1741.05 Cr	3449.65 Cr
Provision for Tax	13.17 Cr	406.85 Cr	50.33 Cr	591.47 Cr
Current Income Tax	244.91 Cr	-553.58 Cr	752.77 Cr	546.1 Cr
Deferred Tax	-231.74 Cr	960.43 Cr	-702.44 Cr	45.37 Cr
Profit After Tax	2139.7 Cr	-99.99 Cr	1690.72 Cr	2858.18 Cr
Consolidated Net Profit	2139.7 Cr	-99.99 Cr	1690.72 Cr	2858.18 Cr
Profit Balance B/F	14005.3 Cr	15964.6 Cr	13612.1 Cr	12790.9 Cr
Appropriations	16145 Cr	15864.6 Cr	15302.8 Cr	15649.1 Cr
Other Appropriation	247.19 Cr	573.43 Cr	712.44 Cr	979.59 Cr
Equity Dividend %	750	1000	1150	1350
Earnings Per Share	8.92	-0.42	7.05	11.91
Adjusted EPS	8.92	-0.42	7.05	11.91

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	2799.37 Cr	4481.32 Cr	9408.43 Cr	11087.9 Cr
Adjustment	1809.85 Cr	1974.95 Cr	2722.56 Cr	1554.4 Cr
Changes In working Capital	2564.09 Cr	1559.05 Cr	-5661.82 Cr	1062.13 Cr
Cash Flow after changes in Working Capital	7173.31 Cr	8015.32 Cr	6469.17 Cr	13704.4 Cr
Cash Flow from Operating Activities	6170.37 Cr	8984.54 Cr	4959.33 Cr	12135 Cr
Cash Flow from Investing Activities	536.22 Cr	-5724.74 Cr	-7943.68 Cr	-690.2 Cr
Cash Flow from Financing Activitie	-5980.48 Cr	-5193.46 Cr	2376.07 Cr	-6710.16 Cr
Net Cash Inflow / Outflow	726.11 Cr	-1933.66 Cr	-608.28 Cr	4734.62 Cr
Opening Cash & Cash Equivalents	5676.61 Cr	6273.03 Cr	4508.25 Cr	4623.73 Cr
Cash & Cash Equivalent of Subsidiaries under liquidations	0	41.45 Cr	566.69 Cr	1.29 Cr
Effect of Foreign Exchange Fluctuations	-129.69 Cr	127.43 Cr	157.07 Cr	-73.99 Cr
Closing Cash & Cash Equivalent	6273.03 Cr	4508.25 Cr	4623.73 Cr	9285.65 Cr

STANDALONE CASH FLOW FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	2152.87 Cr	306.86 Cr	1741.05 Cr	3449.65 Cr
Adjustment	970.42 Cr	1266.29 Cr	4823.4 Cr	1768.91 Cr
Changes In working Capital	-1148.37 Cr	3903.67 Cr	-5625.38 Cr	-5169.11 Cr
Cash Flow after changes in Working Capital	1974.92 Cr	5476.82 Cr	939.07 Cr	49.45 Cr
Cash Flow from Operating Activities	1737.25 Cr	7636.36 Cr	507.08 Cr	-292.42 Cr
Cash Flow from Investing Activities	-601.8 Cr	-2702.1 Cr	-705.17 Cr	-262.91 Cr
Cash Flow from Financing Activitie	-1126.29 Cr	-4870.85 Cr	169.31 Cr	473.95 Cr
Net Cash Inflow / Outflow	9.16 Cr	63.41 Cr	-28.78 Cr	-81.38 Cr
Opening Cash & Cash Equivalents	220.5 Cr	351.06 Cr	419.53 Cr	410.28 Cr
Effect of Foreign Exchange Fluctuations	-7.32 Cr	5.06 Cr	19.53 Cr	-2.44 Cr
Closing Cash & Cash Equivalent	222.34 Cr	419.53 Cr	410.28 Cr	326.46 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr
Equity - Authorised	599 Cr	599 Cr	599 Cr	599 Cr
Equity - Issued	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr
Equity Paid Up	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr
Face Value	1	1	1	1
Total Reserves	46222.8 Cr	47771.3 Cr	55755.4 Cr	63426.8 Cr
Securities Premium	1187.41 Cr	1187.41 Cr	1187.41 Cr	1187.41 Cr
Capital Reserves	368.17 Cr	368.17 Cr	368.17 Cr	368.17 Cr
Profit & Loss Account Balance	36598.1 Cr	37645.6 Cr	43610.2 Cr	50154.6 Cr
General Reserves	3562.1 Cr	3562.1 Cr	3562.1 Cr	3562.1 Cr
Reserve excluding Revaluation Reserve	46222.8 Cr	47771.3 Cr	55755.4 Cr	63426.8 Cr
Shareholder's Funds	46462.8 Cr	48011.2 Cr	55995.4 Cr	63666.8 Cr
Minority Interest	3017.05 Cr	3054.89 Cr	3320.09 Cr	3439.22 Cr
Secured Loans	7.83 Cr	0	0	0
Unsecured Loans	890.3 Cr	229.92 Cr	0	1.33 Cr
Loans - Banks	646.88 Cr	229.92 Cr	0	0
Loans - Others	0	0	0	1.33 Cr
Deferred Tax Assets / Liabilities	-3511.93 Cr	-2864.86 Cr	-3132.55 Cr	-3948.59 Cr
Deferred Tax Assets	4712.19 Cr	4478.31 Cr	5409.36 Cr	6077.63 Cr
Deferred Tax Liability	1200.26 Cr	1613.45 Cr	2276.81 Cr	2129.04 Cr
Other Long Term Liabilities	771.51 Cr	902.36 Cr	1146.52 Cr	802.23 Cr
Long Term Provisions	327.12 Cr	369.07 Cr	342.91 Cr	413.89 Cr
Total Non-Current Liabilities	-1515.17 Cr	-1363.51 Cr	-1643.12 Cr	-2731.14 Cr
Trade Payables	3973.66 Cr	4479.34 Cr	5681.52 Cr	5653.3 Cr
Sundry Creditors	3973.66 Cr	4479.34 Cr	5681.52 Cr	5653.3 Cr
Other Current Liabilities	4965.34 Cr	2926.73 Cr	2603.51 Cr	2716.85 Cr
Advances received from customers	47.19 Cr	28.58 Cr	41.02 Cr	43.33 Cr
Interest Accrued But Not Due	4.71 Cr	2.9 Cr	21.69 Cr	6.94 Cr
Short Term Borrowings	2444.9 Cr	468.52 Cr	5958.26 Cr	2844.36 Cr
Short Term Provisions	4761.73 Cr	9325.96 Cr	5663.09 Cr	5769.26 Cr
Provision for Tax	179.08 Cr	178.14 Cr	308.71 Cr	411.7 Cr
Provision for post retirement benefits	458.87 Cr	427.33 Cr	470.27 Cr	0
Total Current Liabilities	16145.6 Cr	17200.6 Cr	19906.4 Cr	16983.8 Cr
Total Liabilities	64110.3 Cr	66903.2 Cr	77579.4 Cr	81359.2 Cr
Gross Block	35579 Cr	38501.9 Cr	43454.6 Cr	44283.7 Cr
Less: Accumulated Depreciation	14026 Cr	16042.2 Cr	19034.5 Cr	21072.3 Cr
Net Block	21553 Cr	22459.7 Cr	24420.1 Cr	23211.4 Cr
Capital Work in Progress	936.52 Cr	797.51 Cr	963.35 Cr	1107.73 Cr
Non Current Investments	6482.39 Cr	5214.65 Cr	5457.48 Cr	6441.23 Cr
Long Term Investment	6482.39 Cr	5214.65 Cr	5457.48 Cr	6441.23 Cr
Quoted	5254.1 Cr	4242.7 Cr	4486.91 Cr	5369.24 Cr
Unquoted	1340.57 Cr	1084.92 Cr	1085.18 Cr	1186.92 Cr
Long Term Loans & Advances	4061.34 Cr	2880.86 Cr	2752.12 Cr	2784.59 Cr
Other Non Current Assets	4.67 Cr	46.12 Cr	93.13 Cr	93.17 Cr
Total Non-Current Assets	33668.2 Cr	31888.2 Cr	37696 Cr	37884.2 Cr
Currents Investments	3130.06 Cr	7633.94 Cr	9372.61 Cr	8584.54 Cr
Quoted	3099.06 Cr	4031.8 Cr	4934.87 Cr	4198.6 Cr
Unquoted	1340.57 Cr	1084.92 Cr	1085.18 Cr	1186.92 Cr
Inventories	8997.02 Cr	8996.81 Cr	10513 Cr	9868.29 Cr
Raw Materials	3344.17 Cr	2913.54 Cr	3478.45 Cr	3129.56 Cr
Work-in Progress	1829.29 Cr	2057.8 Cr	2497.38 Cr	2009.76 Cr
Finished Goods	2975.63 Cr	3064.81 Cr	3451.09 Cr	3734.5 Cr
Stores and Spare	107.25 Cr	122.38 Cr	131.05 Cr	148.2 Cr
Sundry Debtors	9061.4 Cr	10592.9 Cr	11438.5 Cr	11249.4 Cr
Debtors more than Six months	0	469.48 Cr	560.51 Cr	656.51 Cr
Debtors Others	9302.44 Cr	10492 Cr	11292.9 Cr	10998.7 Cr
Cash and Bank	6445.51 Cr	5033.35 Cr	5770.29 Cr	10520.7 Cr
Cash in hand	1.41 Cr	1.52 Cr	2.14 Cr	1.8 Cr
Balances at Bank	6415.02 Cr	5017.75 Cr	5758.66 Cr	10496.4 Cr
Other Current Assets	1319.11 Cr	1065.44 Cr	745.91 Cr	755.99 Cr
Interest accrued on Investments	6.34 Cr	10.48 Cr	32.5 Cr	42.73 Cr
Prepaid Expenses	278.7 Cr	286.22 Cr	371.77 Cr	413.54 Cr
Short Term Loans and Advances	1488.98 Cr	1692.55 Cr	2021.57 Cr	2454.24 Cr
Advances recoverable in cash or in kind	441.16 Cr	405.13 Cr	545.44 Cr	515.19 Cr
Total Current Assets	30442.1 Cr	35015 Cr	39861.9 Cr	43433.1 Cr
Net Current Assets (Including Current Investments)	14296.4 Cr	17814.4 Cr	19955.6 Cr	26449.3 Cr
Total Assets	64110.3 Cr	66903.2 Cr	77579.4 Cr	81359.2 Cr
Contingent Liabilities	4582.97 Cr	3647.11 Cr	4061.31 Cr	4567.19 Cr
Total Debt	3766.91 Cr	930.69 Cr	6197.88 Cr	2845.69 Cr
Book Value	193.65	0	233.38	265.36
Adjusted Book Value	193.65	200.11	233.38	265.36

STANDALONE BALANCE SHEET FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr
Equity - Authorised	599 Cr	599 Cr	599 Cr	599 Cr
Equity - Issued	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr
Equity Paid Up	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr
Face Value	1	1	1	1
Total Reserves	24800.2 Cr	24348 Cr	23508.4 Cr	23454.5 Cr
Securities Premium	1187.41 Cr	1187.41 Cr	1187.41 Cr	1187.41 Cr
Capital Reserves	5357.52 Cr	2225.85 Cr	2225.85 Cr	2225.85 Cr
Profit & Loss Account Balance	14578.6 Cr	13612.1 Cr	12790.9 Cr	12731 Cr
General Reserves	3477.93 Cr	5143.5 Cr	5143.5 Cr	5143.5 Cr
Reserve excluding Revaluation Reserve	24800.2 Cr	24348 Cr	23508.4 Cr	23454.5 Cr
Shareholder's Funds	25040.2 Cr	24588 Cr	23748.4 Cr	23694.4 Cr
Secured Loans	5.41 Cr	0	0	0
Unsecured Loans	4828.15 Cr	4865.64 Cr	7586.73 Cr	11036 Cr
Loans and advances from subsidiaries	0	4865.64 Cr	7586.73 Cr	11036 Cr
Loans - Banks	182.58 Cr	0	0	0
Loans - Others	4442.73 Cr	0	0	0
Deferred Tax Assets / Liabilities	-1337.45 Cr	-324.04 Cr	-1032.39 Cr	-994.52 Cr
Deferred Tax Assets	1970.32 Cr	1389.47 Cr	1982.84 Cr	1826.56 Cr
Deferred Tax Liability	632.87 Cr	1065.43 Cr	950.45 Cr	832.04 Cr
Other Long Term Liabilities	160.72 Cr	808.43 Cr	1080.18 Cr	1669.51 Cr
Long Term Provisions	2341.36 Cr	1013.82 Cr	1594.25 Cr	2134.8 Cr
Total Non-Current Liabilities	5998.19 Cr	6363.85 Cr	9228.77 Cr	13845.8 Cr
Trade Payables	2592.61 Cr	2710.44 Cr	3125.58 Cr	2619.58 Cr
Sundry Creditors	2592.61 Cr	2710.44 Cr	3125.58 Cr	2619.58 Cr
Other Current Liabilities	2895.29 Cr	4829.77 Cr	4424.42 Cr	1205.25 Cr
Advances received from customers	207.19 Cr	348.06 Cr	71.4 Cr	19.1 Cr
Interest Accrued But Not Due	1.36 Cr	0	0	0
Short Term Borrowings	1651.98 Cr	3.07 Cr	5.94 Cr	10.6 Cr
Short Term Provisions	1203.67 Cr	2562.55 Cr	809.5 Cr	609.08 Cr
Provision for post retirement benefits	88.46 Cr	140.17 Cr	145.73 Cr	0
Total Current Liabilities	8343.55 Cr	10105.8 Cr	8365.44 Cr	4444.51 Cr
Total Liabilities	39381.9 Cr	41057.6 Cr	41343.2 Cr	41985.3 Cr
Gross Block	8776.2 Cr	17195 Cr	17744.7 Cr	18251.7 Cr
Less: Accumulated Depreciation	3531.84 Cr	7482.2 Cr	9033.01 Cr	10515 Cr
Net Block	5244.36 Cr	9712.78 Cr	8711.67 Cr	7736.74 Cr
Capital Work in Progress	442.85 Cr	358.94 Cr	328.87 Cr	388.24 Cr
Non Current Investments	16967.7 Cr	15355.8 Cr	12416.1 Cr	12430 Cr
Long Term Investment	16967.7 Cr	15355.8 Cr	12416.1 Cr	12430 Cr
Quoted	340.87 Cr	352.04 Cr	343.02 Cr	343.5 Cr
Unquoted	16910.4 Cr	18446.4 Cr	18453.5 Cr	18466.8 Cr
Long Term Loans & Advances	4339.17 Cr	5451.94 Cr	2882.26 Cr	6077.91 Cr
Other Non Current Assets	1.56 Cr	4.69 Cr	15.06 Cr	20.2 Cr
Total Non-Current Assets	27315.6 Cr	31353.9 Cr	24878 Cr	27030.9 Cr
Currents Investments	31 Cr	193.04 Cr	200.26 Cr	0
Unquoted	16910.4 Cr	18446.4 Cr	18453.5 Cr	18466.8 Cr
Inventories	3165.72 Cr	3403.74 Cr	3989.19 Cr	3423.62 Cr
Raw Materials	1460.14 Cr	1413.87 Cr	1751.3 Cr	1369.12 Cr
Work-in Progress	1019.89 Cr	1124.63 Cr	1489.72 Cr	1157.55 Cr
Finished Goods	509.22 Cr	726.15 Cr	612.16 Cr	780.84 Cr
Packing Materials	0	0	0	67.08 Cr
Stores and Spare	38.59 Cr	42.01 Cr	52.1 Cr	49.03 Cr
Sundry Debtors	6370.62 Cr	4245.16 Cr	7125.02 Cr	8834.16 Cr
Debtors more than Six months	0	698.86 Cr	1319.64 Cr	1825.05 Cr
Debtors Others	6495.77 Cr	3680.47 Cr	5884.26 Cr	7077.28 Cr
Cash and Bank	232.26 Cr	534.96 Cr	421.28 Cr	338.39 Cr
Cash in hand	73 Lk	86 Lk	1.62 Cr	1.19 Cr
Balances at Bank	231.53 Cr	534.1 Cr	419.66 Cr	337.2 Cr
Other Current Assets	1009.08 Cr	591.3 Cr	367.97 Cr	420.3 Cr
Interest accrued and or due on loans	2 Cr	8.58 Cr	26.1 Cr	23.16 Cr
Prepaid Expenses	112.74 Cr	137.47 Cr	140.24 Cr	168.36 Cr
Short Term Loans and Advances	1257.66 Cr	735.55 Cr	4340.03 Cr	1896.07 Cr
Advances recoverable in cash or in kind	142.11 Cr	299.37 Cr	396.83 Cr	454.61 Cr
Total Current Assets	12066.3 Cr	9703.75 Cr	16443.8 Cr	14912.5 Cr
Net Current Assets (Including Current Investments)	3722.79 Cr	-402.08 Cr	8078.31 Cr	10468 Cr
Total Assets	39381.9 Cr	41057.6 Cr	41343.2 Cr	41985.3 Cr
Contingent Liabilities	3031.66 Cr	999.12 Cr	937.72 Cr	888.89 Cr
Total Debt	6670.01 Cr	4868.71 Cr	7592.67 Cr	11046.6 Cr
Book Value	104.36	0	98.98	0
Adjusted Book Value	104.36	102.48	98.98	98.76

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	12.1	13.64	35.32	39.91
CEPS(Rs)	18.19	23.13	46.22	50.87
DPS(Rs)	7.5	10	11.5	13.5
Book NAV/Share(Rs)	193.65	200.11	233.38	265.36
Tax Rate(%)	18.39	24	9.01	12.98
Margin Ratios
Core EBITDA Margin(%)	13.78	14.71	15.44	26.29
EBIT Margin(%)	4.78	6.86	12.9	23.35
Pre Tax Margin(%)	4.55	6.67	12.67	22.86
PAT Margin (%)	3.72	5.07	11.53	19.9
Cash Profit Margin (%)	7.1	8.26	14.94	25.17
Performance Ratios
ROA(%)	3.54	5.2	11.85	12.17
ROE(%)	4.98	7.21	16.46	16.13
ROCE(%)	5.67	9.32	17.24	17.6
Asset Turnover(x)	0.95	1.03	1.03	0.61
Sales/Fixed Asset(x)	1.74	1.81	1.81	1.11
Working Capital/Sales(x)	4.3	3.77	3.72	1.83
Efficiency Ratios
Fixed Capital/Sales(x)	0.58	0.55	0.55	0.9
Receivable days	54.88	53.38	53.89	85.38
Inventory Days	50.1	48.87	47.78	76.7
Payable days	58.14	149.03	174.1	194.01
Valuation Parameters
PER(x)	49.38	67.07	27.84	40.6
PCE(x)	32.85	39.55	21.27	31.86
Price/Book(x)	3.09	4.57	4.21	6.11
Yield(%)	1.26	1.09	1.17	0.83
EV/Net Sales(x)	4.2	5.57	5.38	7.86
EV/Core EBITDA(x)	15.09	19.03	19.24	26.51
EV/EBIT(x)	47.85	46.73	24.67	33.65
EV/CE(x)	2.19	3.22	3.05	5.73
M Cap / Sales	4.28	5.68	5.37	8.02
Growth Ratio
Net Sales Growth(%)	2.01	15.39	13.53	10.51
Core EBITDA Growth(%)	22.31	21.36	8.5	17.07
EBIT Growth(%)	-44.64	56.71	107.88	18.22
PAT Growth(%)	-45.43	49.07	151.36	12.7
EPS Growth(%)	-22.87	12.7	158.91	13.01
Financial Stability Ratios
Total Debt/Equity(x)	0.08	0.02	0.11	0.04
Current Ratio(x)	1.89	2.04	2	2.56
Quick Ratio(x)	1.33	1.51	1.47	1.98
Interest Cover(x)	20.79	36.19	55.7	47.5
Total Debt/Mcap(x)	0.03	0	0.03	0.01

FINANCIAL RATIOS (STANDALONE) FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	8.92	-0.42	7.05	11.91
CEPS(Rs)	11.36	5.21	13.72	18.58
DPS(Rs)	7.5	10	11.5	13.5
Book NAV/Share(Rs)	104.36	102.48	98.98	98.76
Tax Rate(%)	0.61	132.59	2.89	17.15
Margin Ratios
Core EBITDA Margin(%)	20.21	16.98	29.5	27.13
EBIT Margin(%)	16.65	4.42	10.17	20.88
Pre Tax Margin(%)	14.88	1.95	8	17.01
PAT Margin (%)	14.79	-0.64	7.77	14.1
Cash Profit Margin (%)	18.84	7.95	15.12	21.99
Performance Ratios
ROA(%)	5.48	-0.23	4.1	6.86
ROE(%)	8.66	-0.39	7	12.05
ROCE(%)	7.71	2.19	7.28	12.81
Asset Turnover(x)	0.37	0.37	0.53	0.49
Sales/Fixed Asset(x)	1.7	0.95	1.25	1.13
Working Capital/Sales(x)	3.89	-39.08	2.7	1.94
Efficiency Ratios
Fixed Capital/Sales(x)	0.59	1.05	0.8	0.89
Receivable days	158.15	125.78	95.31	143.65
Inventory Days	73.15	79.29	61.97	66.72
Payable days	92.27	217.66	175.92	187.09
Valuation Parameters
PER(x)	67.01	0	139.51	136.03
PCE(x)	52.59	175.6	71.66	87.2
Price/Book(x)	5.73	8.93	9.93	16.41
Yield(%)	1.26	1.09	1.17	0.83
EV/Net Sales(x)	11.7	14.36	11.68	19.7
EV/Core EBITDA(x)	48.54	57.9	36	66
EV/EBIT(x)	62.17	322.06	109.82	94.36
EV/CE(x)	3.8	5.45	5.88	11.5
M Cap / Sales	11.2	14.08	11.33	19.18
Growth Ratio
Net Sales Growth(%)	2.16	10.41	33.53	-2.58
Core EBITDA Growth(%)	-26.91	57.83	74.67	-10.35
EBIT Growth(%)	-34.18	-38.12	218.47	91.29
PAT Growth(%)	-33.37	-111.87	1790.89	69.05
EPS Growth(%)	-33.37	-111.87	1791.07	69.05
Financial Stability Ratios
Total Debt/Equity(x)	0.27	0.2	0.32	0.47
Current Ratio(x)	1.45	0.96	1.97	3.36
Quick Ratio(x)	1.07	0.62	1.49	2.59
Interest Cover(x)	9.38	1.79	4.69	5.4
Total Debt/Mcap(x)	0.05	0.02	0.03	0.03

SHARE HOLDING PATTERN FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48
FII %	14.95	15.99	16.87	16.88	16.48	16.78	17.08	17.72	17.23	18.01
DII %	0.09	0.10	0.11	0.13	0.15	0.20	0.22	0.21	0.20	0.20
Public %	10.91	9.88	9.51	9.39	9.29	9.07	8.92	8.97	9.02	8.90

PEER COMPARISON FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR SUN PHARMACEUTICAL

Exchange Date	Purpose	Book Closure Dates
BSE 09-Oct-2024	Board Meeting - Quarterly Results	28-Oct-2024
BSE 15-Jul-2024	Board Meeting - Quarterly Results	01-Aug-2024
BSE 22-May-2024	Dividend - Rs.5.0000 per share(500%)Final Dividend
BSE 13-May-2024	Board Meeting - Final Dividend & Audited Results	22-May-2024
BSE 09-Feb-2024	Dividend - Interim Dividend
BSE 15-Jan-2024	Board Meeting - Interim Dividend & Quarterly Results	31-Jan-2024
BSE 18-Dec-2023	SAST - Intimation of agreement to acquire stake in Lyndra Therapeutics, Inc.
BSE 13-Oct-2023	Board Meeting - Quarterly Results	01-Nov-2023
BSE 06-Oct-2023	SAST - Acquisition and Update on Acquisition
BSE 28-Jul-2023	Dividend - Rs.4.0000 per share(400%)Final Dividend
BSE 11-Jul-2023	Board Meeting - Quarterly Results	03-Aug-2023
BSE 11-May-2023	Board Meeting - Final Dividend & Audited Results	26-May-2023
BSE 24-Mar-2023	SAST - This is to inform you that Sun Pharmaceutical Industries Limited (which includes its subsidiaries and/or associate companies) ('Company') has entered into an agreement to acquire 60% shareholding in Vivaldis Health And Foods Private Limited from its existing shareholders with remaining 40% shareholding to be acquired in future as per certain terms & conditions. The particulars of the disclosure re...
BSE 06-Mar-2023	SAST - Sun Pharma Completes Acquisition of Concert Pharmaceuticals
BSE 20-Feb-2023	SAST - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 1. Agreement to acquire equity shares (up to 26.09%) of Agatsa Software Private Limited, which is is an early-stage digital diagnostic devices company. 2. Agreement to acquire equity shares (27.39%) of Remidio Innovative Solutions Private Limited, which provides innovative products enabling e...
BSE 20-Jan-2023	SAST - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Agreement to Acquire Concert Pharmaceuticals, Inc.
BSE 16-Jan-2023	Board Meeting - Quarterly Results & Interim Dividend	31-Jan-2023
BSE 16-Jan-2023	Dividend - Interim Dividend
BSE 10-Oct-2022	Board Meeting - Quarterly Results	01-Nov-2022
BSE 28-Sep-2022	SAST - Further to the Press Release submitted vide our letter dated May 27, 2022, we wish to inform that the acquisition of UractivTM Portfolio from Fiterman Pharma inRomania closed on September 27, 2022.
BSE 12-Jul-2022	Board Meeting - Quarterly Results	29-Jul-2022
BSE 31-May-2022	Dividend - Rs.3.0000 per share(300%)Final Dividend
BSE 12-May-2022	Board Meeting - Final Dividend & Audited Results	30-May-2022
BSE 08-Mar-2022	SAST - Update on Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
BSE 09-Feb-2022	Dividend - Rs.7.0000 per share(700%)Interim Dividend
BSE 17-Jan-2022	Board Meeting - Quarterly Results	31-Jan-2022
BSE 12-Oct-2021	Board Meeting - Quarterly Results	02-Nov-2021

CORPORATE ANNOUNCEMENTS FOR SUN PHARMACEUTICAL

Exchange Date	Category File	Description
BSE 29-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issuance of Letter of Confirmation.
BSE 28-Oct-2024	General Announcements FILE	Q2FY25 Investor Call Audio Recording Q2FY25 Investor Call Audio Recording
BSE 28-Oct-2024	Outcome FILE	Financial Results For The Quarter And Half Year Ended September 30 2024 Financial results for quarter and half year ended September 30 2024
BSE 25-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Winlevi poster presentation at 2024 Fall Clinical Dermatology conference.
BSE 25-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Sun Pharma presents LEQSELVI data at the 2024 Fall Clinical Dermatology Conference.
BSE 18-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issuance of Duplicate Share Certificate
BSE 15-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Sun Pharma to announce second quarter results on October 28 2024
BSE 11-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Issue of Letter of Confirmation
BSE 11-Oct-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Regulatory Order Intimation regarding update on Regulatory Order
BSE 10-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Intimation regarding Compliance Certificate.
BSE 10-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate.
BSE 09-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Loss of Share Certificate
BSE 09-Oct-2024	Intimation FILE	Board Meeting Intimation for Approval Of Financial Results SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve Financial Results for the quarter and half year ended September 30 2024
BSE 08-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Loss of Share Certificate
BSE 07-Oct-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Order Intimation regarding order passed by Regulatory Authority
BSE 01-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release - Sun Pharma and Philogen enter into a global Exclusive Commercialization License and supply agreement for commercializing the speciality product FIBROMUN
BSE 30-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation
BSE 26-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Sun Pharma presents new clinical efficacy and safety data at 2024 EADV congress.
BSE 25-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Loss of Share Certificate.
BSE 24-Sep-2024	Intimation FILE	Closure of Trading Window Intimation regarding Closure of Trading Window.
BSE 23-Sep-2024	General Announcements FILE	Response To Your Email On Increase In Volume Response to BSE on increase in volume
BSE 23-Sep-2024	General -	Clarification sought from Sun Pharmaceutical Industries Ltd The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on September 23 2024 with reference to Movement in Volume.The reply is awaited.
BSE 20-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Issuance of Duplicate Share Certificate
BSE 18-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Loss of Certificate
BSE 17-Sep-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Order Intimation regarding Regulatory Orders
BSE 16-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of schedule of Analyst/Institutional Investor Meeting
BSE 13-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Issuance of Letter of Confirmation
BSE 10-Sep-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Order Intimation regarding regulatory order
BSE 06-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Intimation regarding press release
BSE 03-Sep-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Order Intimation regarding order passed by Regulatory Authority

INSIDER TRADING FOR SUN PHARMACEUTICAL

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 22-Dec-2022 22-Dec-2022	Sell Market	5,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 23-Dec-2022 23-Dec-2022	Sell Market	2,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 06-Dec-2022 06-Dec-2022	Sell Market	3,000 @ 0.00 (0.00 %)	Priti Gandhi
BSE 06-Dec-2022 06-Dec-2022	Sell Market	2,000 @ 0.00 (0.00 %)	Nilesh Gandhi
BSE 29-Nov-2022 29-Nov-2022	Sell Market	6,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 29-Nov-2022 29-Nov-2022	Sell Market	1,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Meera Desai wife of Sailesh T Desai WTD is a Partner
BSE 24-Nov-2022 24-Nov-2022	Sell Market	10,000 @ 0.00 (0.01 %)	Sailesh T Desai
BSE 30-Sep-2022 30-Sep-2022	Sell Market	1,500 @ 0.00 (0.00 %)	Julie R Shah
BSE 28-Sep-2022 28-Sep-2022	Sell Market	2,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 28-Sep-2022 28-Sep-2022	Sell Market	14,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 21-Sep-2022 21-Sep-2022	Sell Market	15,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 31-Mar-2022 31-Mar-2022	Sell Market	2,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 22-Mar-2022 22-Mar-2022	Buy Gift	11,000 @ 0.00 (0.00 %)	Julie R Shah
BSE 21-Mar-2022 21-Mar-2022	Sell Market	12,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 17-Mar-2022 17-Mar-2022	Sell Market	15,400 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 07-Feb-2022 07-Feb-2022	Sell Gift	200,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 31-Dec-2021 31-Dec-2021	Sell Market	2,000 @ 0.00 (0.00 %)	Julie R Shah
BSE 29-Dec-2021 29-Dec-2021	Sell Market	10,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 31-Dec-2021 31-Dec-2021	Sell Market	6,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 28-Dec-2021 29-Dec-2021	Sell Market	3,000 @ 0.00 (0.00 %)	Julie R Shah
BSE 29-Dec-2021 29-Dec-2021	Sell Market	17,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 31-Dec-2021 31-Dec-2021	Sell Market	7,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 27-Dec-2021 27-Dec-2021	Sell Market	3,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 28-Dec-2021 28-Dec-2021	Sell Market	16,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 28-Dec-2021 28-Dec-2021	Sell Market	13,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 22-Dec-2021 22-Dec-2021	Sell Market	10,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 22-Dec-2021 22-Dec-2021	Sell Market	5,000 @ 0.00 (0.00 %)	Sailesh T Desai
BSE 20-Dec-2021 20-Dec-2021	Sell Market	2,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 21-Dec-2021 21-Dec-2021	Sell Market	4,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners
BSE 15-Dec-2021 15-Dec-2021	Sell Market	2,000 @ 0.00 (0.00 %)	Desai Associates Partnership firm in which Ms Meera Desai wife of Sailesh T Desai Whole-time Director is one of the partners

BULK BLOCK DEALS FOR SUN PHARMACEUTICAL INDUSTRIES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 27-Feb-2024	Sell BLOCK	656,286 @ 1556.95	JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED
BSE 27-Feb-2024	Buy BLOCK	656,286 @ 1556.95	THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT
BSE 25-Jan-2024	Sell BLOCK	3,253,896 @ 1382.10	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Buy BLOCK	3,253,896 @ 1382.10	SOCIETE GENERALE
BSE 19-Sep-2022	Sell BLOCK	789,668 @ 868.05	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	789,668 @ 868.05	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 01-Aug-2022	Sell BLOCK	1,133,548 @ 943.20	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 01-Aug-2022	Buy BLOCK	1,133,548 @ 943.20	ISHARES MSCI INDIA ETF
BSE 01-Aug-2022	Buy BLOCK	167,748 @ 943.20	MERRILL LYNCH DEVELOPING CAPITAL MARKET FUND INC
BSE 01-Aug-2022	Sell BLOCK	167,748 @ 943.20	MERRILL LYNCH DEVELOPING CAPITAL MARKET FUND INC
BSE 18-Jul-2022	Buy BLOCK	167,748 @ 878.40	ISHARES INDIA 50 ETF
BSE 18-Jul-2022	Sell BLOCK	1,140,361 @ 878.40	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 18-Jul-2022	Sell BLOCK	167,748 @ 878.40	ISHARES INDIA MAURITIUS CO
BSE 18-Jul-2022	Buy BLOCK	1,140,361 @ 878.40	ISHARES MSCI INDIA ETF
BSE 04-May-2022	Buy BLOCK	1,016,148 @ 923.40	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	1,016,148 @ 923.40	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO
BSE 20-Oct-2021	Sell BLOCK	773,624 @ 827.35	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 20-Oct-2021	Buy BLOCK	773,624 @ 827.35	ISHARES MSCI EMERGING MARKETS ETF
BSE 11-Oct-2021	Sell BLOCK	773,625 @ 821.40	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 11-Oct-2021	Buy BLOCK	773,625 @ 821.40	ISHARES MSCI EMERGING MARKETS ETF
BSE 23-Sep-2021	Sell BLOCK	787,443 @ 770.10	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 23-Sep-2021	Buy BLOCK	787,443 @ 770.10	ISHARES MSCI EMERGING MARKETS ETF
BSE 31-Aug-2021	Buy BLOCK	162,617 @ 787.20	TEACHER RETIREMENT SYSTEM OF TEXAS
BSE 31-Aug-2021	Sell BLOCK	162,617 @ 787.20	TEACHER RETIREMENT SYSTEM OF TEXAS

DIVIDEND BY SUN PHARMACEUTICAL INDUSTRIES LIMITED

Ex Dividend Date	Dividend Type	Dividend
06-Feb-2025	INTERIM DIVIDEND	10.5
12-Jul-2024	DIVIDEND	5
09-Feb-2024	INTERIM DIVIDEND	8.5
28-Jul-2023	DIVIDEND	4
08-Feb-2023	INTERIM DIVIDEND	7.5
19-Aug-2022	DIVIDEND	3
09-Feb-2022	INTERIM DIVIDEND	7
23-Aug-2021	DIVIDEND	2
09-Feb-2021	INTERIM DIVIDEND	5.5